Xencor appoints Raymond Deshaies, Ph.D. to board of directors

Xencor Inc

Dr. Deshaies is a former SVP of global research at Amgen with 25+ years in biotech.
Received initial option grant with $550,000 Black-Scholes value; vests over 3 years.
Also receives $50,000 annual cash retainer; standard indemnification agreement.
Deshaies co-founded Proteolix (discovered carfilzomib/KYPROLIS) and Cleave Biosciences.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.